These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 26914961)
1. Clinical Uses of Intrathecal Therapy and Its Placement in the Pain Care Algorithm. Pope JE; Deer TR; Bruel BM; Falowski S Pain Pract; 2016 Nov; 16(8):1092-1106. PubMed ID: 26914961 [TBL] [Abstract][Full Text] [Related]
3. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study. Deer TR; Kim C; Bowman R; Tolentino D; Stewart C; Tolentino W Pain Physician; 2009; 12(4):E291-6. PubMed ID: 19668287 [TBL] [Abstract][Full Text] [Related]
4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
5. Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain. Saulino M; Kim PS; Shaw E J Pain Res; 2014; 7():627-38. PubMed ID: 25419158 [TBL] [Abstract][Full Text] [Related]
6. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options. Deer TR; Pope JE; Hanes MC; McDowell GC Pain Med; 2019 Apr; 20(4):784-798. PubMed ID: 30137539 [TBL] [Abstract][Full Text] [Related]
7. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects. Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373 [TBL] [Abstract][Full Text] [Related]
8. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Wallace MS Expert Rev Neurother; 2006 Oct; 6(10):1423-8. PubMed ID: 17078783 [TBL] [Abstract][Full Text] [Related]
10. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Thompson JC; Dunbar E; Laye RR Pain Physician; 2006 Apr; 9(2):147-52. PubMed ID: 16703976 [TBL] [Abstract][Full Text] [Related]
11. Role of primary care physicians in intrathecal pain management: a narrative review of the literature. McDowell GC; Winchell J Postgrad Med; 2018 May; 130(4):411-419. PubMed ID: 29542370 [TBL] [Abstract][Full Text] [Related]
12. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508 [TBL] [Abstract][Full Text] [Related]
13. Intrathecal drug administration in chronic pain syndromes. Ver Donck A; Vranken JH; Puylaert M; Hayek S; Mekhail N; Van Zundert J Pain Pract; 2014 Jun; 14(5):461-76. PubMed ID: 24118774 [TBL] [Abstract][Full Text] [Related]
14. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Wermeling DP Pharmacotherapy; 2005 Aug; 25(8):1084-94. PubMed ID: 16207099 [TBL] [Abstract][Full Text] [Related]
15. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507 [TBL] [Abstract][Full Text] [Related]